Occam Places Brian Piekos as CFO of Elicio Therapeutics
Elicio Therapeutics (Nasdaq: ELTX) is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, using its proprietary lymph node-targeting Amphiphile technology. Occam placed Brian Piekos as the company's Chief Financial Officer, in parallel with the closing of Elicio's previously announced merger with Angion Biomedica Corp.
Brian brings well-honed operational discipline and capital markets wisdom to the party. Most recently, Brian served as CFO of Gemini Therapeutics. Prior to joining Gemini, Brian was CFO at AMAG Pharmaceuticals upon the company’s sale in November 2021. Before that, Brian held leadership roles in Corporate Finance, Tax and Treasury at Cubist Pharmaceuticals. He began his career as a healthcare investment banker at Needham & Company and Leerink Partners.
Elicio is a longstanding client of Occam's. Previous placements include Head of R&D and Chief Medical Officer Chris Haqq, Chief Business Officer Annette Matthies, and Board Director Daphne Karydas.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.